Medtech layoffs are picking up as 2024 draws to a close. Sean Whooley, Associate Editor, and Chris Newmarker, Editor-in-Chief The medical device industry is closing out the year with a fresh round of layoffs. At this point, MassDevice has reported on more than 22,000 medtech job cuts across the industry since mid-2022. (Have a tip […]
Better Therapeutics
Click Therapeutics buys shuttered Better Therapeutics’ assets
Click Therapeutics announced today that it acquired the assets of Better Therapeutics to accelerate its digital therapeutic development initiatives. Better Therapeutics’ assets include digital therapeutics for obesity and cardiometabolic disease. The company offered the AspyreRx (BT-001) FDA-authorized prescription digital therapeutic (PDT) for type 2 diabetes. Its assets also include BT-004, a liver disease therapeutic that […]
Better Therapeutics terminates staff as it seeks alternative options
Better Therapeutics (Nasdaq:BTTX) announced today that it is terminating its employees and will explore strategic alternatives. Among those alternatives, the company could consider assignment for the benefit of creditors and/or a wind-down of the company. The San Francisco-based digital therapeutics maker came to the decision at a special meeting of its board on March 13. […]
Better Therapeutics wins FDA breakthrough nod for liver disease-treating digital therapeutic
Better Therapeutics (Nasdaq:BTTX) announced today that the FDA granted breakthrough device designation for its MASH treatment. The company’s prescription digital therapeutic (PDT) delivers novel cognitive behavioral therapy (CBT). It aims to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. This novel form of CBT targets the lifestyle behaviors known to cause and/or […]
Better Therapeutics, Glooko partner on digital diabetes management
Better Therapeutics and Glooko today announced a partnership to integrate technologies and enhance diabetes management. The partnership aims to integrate Better Therapeutics’ ApsyreRx digital behavioral treatment into Glooko’s diabetes management platform. Better Therapeutics designed AspyreRx to treat type 2 diabetes. The FDA authorized AspyreRx as a prescription digital therapeutic for diabetes in July. Palo Alto, […]
Better Therapeutics launches diabetes digital therapeutic platform
Better Therapeutics (Nasdaq:BTTX) announced today that it commercially launched its AspyreRx digital diabetes therapeutic app. AspyreRx became the first cognitive behavioral therapy (CBT) to receive FDA authorization for treating type 2 diabetes in July. The prescription digital therapeutic (PDT) underwent review through the FDA de novo pathway. AspyreRx therapy — formerly BT-001 — provides CBT […]
Better Therapeutics wins FDA nod for type 2 diabetes digital therapeutic
Better Therapeutics (Nasdaq:BTTX) announced that the FDA authorized its AspyreRx prescription digital therapeutic for diabetes. AspyreRx — formerly BT-001 — provides cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The prescription-only digital therapeutic (PDT) underwent review through the FDA de novo pathway. The company submitted an FDA de novo request in […]
Better Therapeutics expects FDA ruling on diabetes digital therapeutic mid-year
Better Therapeutics (Nasdaq:BTTX) shares fell today after its first-quarter earnings report included a wide-ranging business update. Shares of BTTX fell 3.2% at 76¢ apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell 0.2%. Better Therapeutics recorded a net loss of $9.4 million, […]
How did medtech SPAC mergers fare?
Over the past few years, special purpose acquisition corporations (SPACs) have found their way into the medtech space. These businesses — built to bring private companies public — raise initial public offerings (IPOs). They then go and acquire existing companies, taking them public in the process. The value of these mergers varies, but some in […]
Better Therapeutics announces $6.5M private placement
Better Therapeutics (Nasdaq:BTTX) today announced a private placement of nearly 7.9 million shares of its common stock. The San Francisco-based digital therapeutic developer priced the shares at $0.825 per share. That represents the closing price of Better Therapeutics’ common stock on April 5, 2023. The private placement totals gross proceeds of approximately $6.5 million. Better […]
Better Therapeutics hopes FDA nod for diabetes digital therapeutic comes in 2023
Better Therapeutics (Nasdaq:BTTX) shares ticked up on fourth-quarter results and projections for its flagship product in 2023. The company’s quarterly results come on the heels of a 35% headcount reduction. Better Therapeutics said the headcount cut comes as part of a cost reduction initiative. It aims to improve its cash runway and “focus on the […]